ProCE Banner Activity

Early Treatment for High-Risk Smoldering MM: Going for a Cure?

Slideset Download
Download this slideset from Shaji Kumar, MD to see the most recent data on optimal management for patients with high-risk smoldering myeloma.

Released: December 04, 2020

Expiration: December 03, 2021

Share

Faculty

Brian G. M. Durie

Brian G. M. Durie, MD

National Director, Hematologic Malignancies and Multiple Myeloma
Aptium Oncology, Inc.
Co-Chair, Myeloma Committee – SWOG
Chairman, International Myeloma Foundation
Specialist, Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Bristol Myers Squibb

GlaxoSmithKline

Karyopharm

Oncopeptides

Partners

International Myeloma Foundation

ProCE Banner

Faculty Disclosure

Primary Author

Brian G. M. Durie, MD

National Director, Hematologic Malignancies and Multiple Myeloma
Aptium Oncology, Inc.
Co-Chair, Myeloma Committee – SWOG
Chairman, International Myeloma Foundation
Specialist, Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota